OUR AIM

Our vision at Accord is to become a leading pan-EMENA generics company by 2021 and have developed a specialty products commercialisation capability.

     

Accord UK

Accord Europe

Accord Worldwide

I-4

INNOVATION

Accord is committed to putting user safety at the heart of our offering. Accord is a dynamic young company unencumbered by past practice and with an appetite for refreshing the way in which safe and efficacious pharmaceuticals are delivered to users, adding innovative features to our concepts and products.

2D Barcode:

Data Matrix is a relatively recent 2- dimensional barcode development. This code has a high data capacity, variable sizing capabilities and ability to withstand harsh environments. It is most commonly used for product identification and lot tracking of pharmaceuticals. Several organisations have recommended the use of Data Matrix due to the advantages it offers:

  • Improved Data Accuracy
  • Faster Data Input and Handling
  • Cost Benefit
  • Flexibility

Different to other companies in the sector, Accord is able to bring closer this advantageous product labelling due to its high technology offering at our manufacturing facilities and product packing site.

PharmaShield® is a system consisting on a superficial plastic sheathing around the vial, going from the reinforced non- PVC base to the vial seal.

Key benefits:

  • Protects from breakage and spillage
  • Protects users from external vial contamination
  • Protects essential product label information
  • The use of non-PVC materials protects the environment
  • Latex free – protects users with sensitivity
  • Reinforced non-PVC base: provides greater stability during manipulation and further reduces risk of breakage if vial dropped

Key benefits of vial seal:

  • No risk of sharp edges that could potentially damage user
  • Minimises potential disruption to crimp as FOC is removed
  • Easy removal of FOC

Other Accord product features

  • Barcode on label: to enhance stock control and reduce potential errors when dispensing the drug
  • Flip-off cap
  • Line code indicates the different strengths available
 

INFRASTRUCTURE

By recognising that our infrastructure must always be appropriate to solving the problem at hand, we have taken a novel approach to our supply of medicines in the fragmented market of Europe. The EU is the world´s biggest trading block encompassing over 550 million people, 27 countries and over 20% of world´s GDP. Whilst each market is very different over the last decade the regulatory procedures required to gain approval to sell pharmaceuticals in the region have been harmonised.

Put simply we produce large batches of common pharmaceutical product at our EMA and FDA approved facilities and then transfer as nude or undifferentiated products to the packing site. This bulk product is then held ready to pack upon requirement able to go to any of the 27 markets.

By employing this scheme we can shorten lead-times to a matter of weeks. This use of infrastructure is far more suitable to the volatile demand environment of the European trading block than conventional supply chains, all part of our i-4 concept.

 

INVENTION

Rather than simply imitating what has gone before we try to take a more inventive approach to product development. As an example we have reformulated Gemcitabine into a highly concentrated form. Whilst several other companies realised that users would prefer a solution versus the original powder product, they took the approach of making the concentration of the solution match that in the SmPC of the original product.

Instead we stepped back and realised that this approach meant a greater quantity of excipients being given to patients, a greater workload on aseptic pharmacy, greater storage requirements and a greater burden to the environment by having to dispose of more material per patient.

Accord developed the 100 mg/ml Gemcitabine solution. This is unique and offers the following advantages over other solution products:

  • Easier to calculate dosing schedules reducing the chance of dosing errors
  • Less time to withdraw the required dose reducing the burden on aseptic pharmacy
  • Four presentation sizes designed to minimise wastage resulting in financial savings
  • Smaller vials resulting in less use of precious storage space and ultimately reducing the material required to be incinerated; an important environmental improvement
  • Less inactive ingredients being given to patient